Activity Overview
This online, on-demand virtual symposium brings together renowned experts in acute myeloid leukemia (AML). In this educational program, these experts present several key abstracts from a recent hematology meeting and recent publications regarding targeted therapies to treat relapsed/refractory AML. Panel discussions about the presented data help learners apply this evidence to personalized treatment plans for patients with AML.
This educational activity is an archive of the live symposium held on April 9, 2026.
Target Audience
This educational activity is directed toward community-based oncologists, advanced practice providers, oncology nurses, and other health care providers involved in the treatment of patients with AML.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess the clinical implications of key mechanistic differences between targeted therapies for AML
- Evaluate the latest efficacy and safety data from recent clinical trials of targeted therapies for AML
- Apply emerging evidence into personalized treatment plans for patients with AML based on disease- and patient-specific considerations
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here